US4943A - Harness-buckle - Google Patents
Harness-buckle Download PDFInfo
- Publication number
- US4943A US4943A US4943DA US4943A US 4943 A US4943 A US 4943A US 4943D A US4943D A US 4943DA US 4943 A US4943 A US 4943A
- Authority
- US
- United States
- Prior art keywords
- tug
- box
- plate
- buckle
- harness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000105975 Antidesma platyphyllum Species 0.000 description 10
- 235000009424 haa Nutrition 0.000 description 10
- 239000002184 metal Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 238000010276 construction Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000010985 leather Substances 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 229910001369 Brass Inorganic materials 0.000 description 2
- 240000009011 Carpobrotus edulis Species 0.000 description 2
- 241000136406 Comones Species 0.000 description 2
- 210000001138 Tears Anatomy 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000284 resting Effects 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A44—HABERDASHERY; JEWELLERY
- A44B—BUTTONS, PINS, BUCKLES, SLIDE FASTENERS, OR THE LIKE
- A44B11/00—Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts
- A44B11/02—Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps
- A44B11/06—Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps with clamping devices
- A44B11/10—Buckles; Similar fasteners for interconnecting straps or the like, e.g. for safety belts frictionally engaging surface of straps with clamping devices sliding wedge
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T24/00—Buckles, buttons, clasps, etc.
- Y10T24/40—Buckles
- Y10T24/4002—Harness
- Y10T24/4012—Clamping
- Y10T24/4019—Sliding part or wedge
Definitions
- I construct a metallic plate with a rough front surface as represented in Fig. 4, and on the back side of this plate I affix the roller e Fig. 5, which runs in grooves near each outer edge of the plate, and is held in its proper place by the cap f, Fig. 5.
- a band g, Figs. 4 and 5 is attached to the front end of this plate through which the tug or draw strap is passed.
- the draw tug i Fig. 1 is passed in at the. small end of lthe box a, leaving the plateresting upon the back side of the box, as shown at k. Fig. l.I
- the plate and roller will be drawn into the taperlng box a, and thus press the tug i i'irmly between the front side of the box and the sliding plate, and an increase of draft upon the tug will increase the pressure upon the tug within the box, thereby holding it iirmly 1n its proper place.
- the plate can be moved upon the tug by taking hold of the band g, Figs. 4 and 5, thus the tug can be lengthened or shortened at pleasure or entirely drawn out of the metallic box.
- the pin c, Figs. 2 and 3 may be dispensed with and the hame tug riveted to an extended portion of the back plate of the metallic box.
- the box may be made of plated metal, plate brass, or sheet iron, or 1t may be cast.
- the plate and roller may be made of either cast or wrought metal, the whole should correspond in size and strength to the purpose for which it is intended.
- the style of finish should also correspond with Vthe other portions of the harness.
- attachments indicated by rthe dotted lines at n, Fig. 3 may be afixed to each side of the box.
- the breech strap may pass into the box with the tug, or which is better, pass through an aperture 0 Fig. 3, in the back plate of the box. This aperture may, if desired, be made in the front plate of the box.
Landscapes
- Package Frames And Binding Bands (AREA)
Description
UNITED` STATES PATENT 'OFFICE WILLIAM D. HILLIS, OF CUYAHOGA FALLS, OHIO.
HARNESS-BUCKLE.
Specification of Letters Patent No. 4,943, dated January 26, 1847.
To all whom t may concern.'
Be it known that I, WILLIAM D. I-IILLrs, of Cuyahoga Falls, in the county of Summit and State of Ohio, have invented a new and Improved Mode of Fastening Tugs or Draw-Straps of Harness to Hame-Tugs; and I do hereby declare that the following is a full and exact description of the construction and operation of the same, reference being had to the annexed drawings, making a part of this specification, in which- Figure l is a perspective view of the model, embracing the hame tug, buckle, and a part of the tug or draw strap. Fig. 2, a perspective view of the buckle detached from the hame tug and draw strap. Figs. 3, 4 and 5 are sectional views of the same in different positions. Figs. 2, 3, 4 and 5 being drawn on a larger scale than Fig. l.
The nature of my invention consists in the construction of an apparatus' which will serve all the purposes of the common buckle, r
without the use of the tongue, and the consequent necessity of perforating the draw strap with holes, and also the convenience of taking up, or adjusting the draw tug to lany desired length.
To enable othersI skilled in the art, to make and use my invention, I will proceed to describe its const-ruct-ion and operation.
I construct a metallic oblong box, let a, Figs. l, 2 and 3, open at bothV ends, of equal width perpendicularly, but of unequal thickness, thefront and back sides of the box forming relatively to each other an inclined plane, the opening in the front end of this box is suiiiciently large to admit the metallic plate and roller hereafterto be described, together with the draw tug or strap.
The parallel sides of the box which are marked b, b, Fig. 3 extend farther than the back plate, and receives the pin c Figs. 2 and 3, around which the hame tug passes as represented at cl, Fig. 1. A
I construct a metallic plate with a rough front surface as represented in Fig. 4, and on the back side of this plate I affix the roller e Fig. 5, which runs in grooves near each outer edge of the plate, and is held in its proper place by the cap f, Fig. 5.
A band g, Figs. 4 and 5 is attached to the front end of this plate through which the tug or draw strap is passed. I Vplace this plate with the roller, inside of the box a,
ythe roller resting upon the back side Vof the A box and ,thel rough side ofl the plate being 1n front as represented at 7L, Fig. 2. The draw tug i Fig. 1 is passed in at the. small end of lthe box a, leaving the plateresting upon the back side of the box, as shown at k. Fig. l.I Now, by pulling upon the tug, the plate and roller will be drawn into the taperlng box a, and thus press the tug i i'irmly between the front side of the box and the sliding plate, and an increase of draft upon the tug will increase the pressure upon the tug within the box, thereby holding it iirmly 1n its proper place. In klengthening or shortening the tug, the plate can be moved upon the tug by taking hold of the band g, Figs. 4 and 5, thus the tug can be lengthened or shortened at pleasure or entirely drawn out of the metallic box.
The sheath m, Fig. l, into which the end of the tug passes after leaving the metal box, is attached as'usual to the hame tug and should extend to the end which is attached to theV metal box.
In theconstruction of this buckle orfastening, the pin c, Figs. 2 and 3 may be dispensed with and the hame tug riveted to an extended portion of the back plate of the metallic box. The box may be made of plated metal, plate brass, or sheet iron, or 1t may be cast. The plate and roller may be made of either cast or wrought metal, the whole should correspond in size and strength to the purpose for which it is intended. The style of finish should also correspond with Vthe other portions of the harness.
If it is desired to fasten the pad and girth y to the tug, attachments indicated by rthe dotted lines at n, Fig. 3, may be afixed to each side of the box. The breech strap may pass into the box with the tug, or which is better, pass through an aperture 0 Fig. 3, in the back plate of the box. This aperture may, if desired, be made in the front plate of the box.
The advantages of this method of fastening over the common tongue buckle, are various, and consist first, in beauty. It will be a great ornament to a harness. Second, in strength, about one half of the strength of t-he common tug is lost by the holes for the buckle tongue. Third, in economy of leather. A tug with this fastening requires about one half the usual quantity of leather for the same strength. Fourth, durability, the tongue of the comon buckle tears, and the ring indents and will soon materially injure the tug. But With this fastening, the large surface pressing the tug, cannot indent it. Fifth, in convenience. The tug may be lengthened or shortened in a moment of time, and with no trouble. Finally, its
advantages over other known methods of fastening the tug, consists in the convenience with which it is Worked, in lengthening or shortening the tug; the little Wear to the tug from the large surface pressing it, and in its being undivided7 and in security, as when the tug is loosened, upon being drawn,
WILLIAM D. HILLIS.
Vitnesses G. C. I-IUBBARD, H. PAUL.
Publications (1)
Publication Number | Publication Date |
---|---|
US4943A true US4943A (en) | 1847-01-26 |
Family
ID=2065244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US4943D Expired - Lifetime US4943A (en) | Harness-buckle |
Country Status (1)
Country | Link |
---|---|
US (1) | US4943A (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070222256A1 (en) * | 2006-03-23 | 2007-09-27 | Jeffrey Valentage | Hybrid door core and trim module with integrated components |
US20090006359A1 (en) * | 2007-06-28 | 2009-01-01 | Oracle International Corporation | Automatically finding acronyms and synonyms in a corpus |
WO2013174432A1 (en) | 2012-05-24 | 2013-11-28 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
EP2687202A1 (en) | 2009-07-31 | 2014-01-22 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
WO2021097110A1 (en) | 2019-11-13 | 2021-05-20 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2021250284A1 (en) | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2022020716A1 (en) | 2020-07-24 | 2022-01-27 | Genentech, Inc. | Heterocyclic inhibitors of tead for treating cancer |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
EP4067347A1 (en) | 2016-05-24 | 2022-10-05 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer |
WO2022251296A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
EP4119583A1 (en) | 2008-01-30 | 2023-01-18 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
EP4335931A2 (en) | 2015-05-29 | 2024-03-13 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024173842A1 (en) | 2023-02-17 | 2024-08-22 | Erasca, Inc. | Kras inhibitors |
-
0
- US US4943D patent/US4943A/en not_active Expired - Lifetime
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
US20070222256A1 (en) * | 2006-03-23 | 2007-09-27 | Jeffrey Valentage | Hybrid door core and trim module with integrated components |
US20090006359A1 (en) * | 2007-06-28 | 2009-01-01 | Oracle International Corporation | Automatically finding acronyms and synonyms in a corpus |
EP4119583A1 (en) | 2008-01-30 | 2023-01-18 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
EP2687202A1 (en) | 2009-07-31 | 2014-01-22 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
EP4339212A2 (en) | 2009-07-31 | 2024-03-20 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
WO2013174432A1 (en) | 2012-05-24 | 2013-11-28 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
EP4335931A2 (en) | 2015-05-29 | 2024-03-13 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4067347A1 (en) | 2016-05-24 | 2022-10-05 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
WO2021097110A1 (en) | 2019-11-13 | 2021-05-20 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2021250284A1 (en) | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2022020716A1 (en) | 2020-07-24 | 2022-01-27 | Genentech, Inc. | Heterocyclic inhibitors of tead for treating cancer |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2022251296A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024173842A1 (en) | 2023-02-17 | 2024-08-22 | Erasca, Inc. | Kras inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4943A (en) | Harness-buckle | |
US377709A (en) | Assighoe to him | |
US600478A (en) | Harness-loop | |
US130604A (en) | Improvement in halters | |
US111502A (en) | Improvement in harness saddle-trees | |
US155796A (en) | Improvement in bridle-rosettes and gag-swivels | |
US392306A (en) | Hame-tug | |
US347533A (en) | Breast-ring attachment | |
US7265A (en) | Habjstess-hahe | |
US385687A (en) | Joseph j | |
US69628A (en) | Improved belt-clasp | |
US113902A (en) | Improvement in buckles | |
US225242A (en) | Harness-saddle | |
US150161A (en) | Improvement in horse-collars | |
US102333A (en) | Improvement in trace-buckles | |
US43931A (en) | Improvement in toilet-combs | |
US350216A (en) | James stanley | |
US356102A (en) | Hame-tug | |
US403947A (en) | Hame-tug | |
USRE7129E (en) | Improvement in buckle-fastenings | |
US206307A (en) | Improvement in shaft-tugs | |
US743492A (en) | Hame-tug. | |
US385082A (en) | Hiram j | |
US118137A (en) | Improvement in harness-saddles | |
US136804A (en) | Improvement in horse-collar caps |